Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Inhaled delivery effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, differentiating our drugs from other treatments.
Company Details
- Employees
- 8
- Address
- Boston, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://alveolusbio.com
- Keywords
- on a global scale..
- HQ
- Boston, MA
Alveolus Bio Questions
Alveolus Bio's website is http://alveolusbio.com
Alveolus Bio's LinkedIn profile is https://www.linkedin.com/company/alveolus-bio
Alveolus Bio has
8 employees.
View email and phone details for 8
employees at Alveolus Bio.
Alveolus Bio's industry is
Biotechnology Research
Alveolus Bio's top competitors are
Biostack Ventures,
Amytrx Therapeutics, Inc.,
Shilpa Medicare Ltd,
Bridge Therapeutics Inc.,
Shilpa Pharma, Inc.,
Maat Pharma,
Vedanta Biosciences, Inc.,
Resbiotic,
Able Biolabs,
Gcv Life.
Alveolus Bio's categories are Biotechnology Research
